A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer

• Published in: Molecular cancer therapeutics Vol. 19; no. 2; pp. 460 - 467
• Main Authors: Sullivan, Ryan J., Hollebecque, Antoine, Flaherty, Keith T., Shapiro, Geoffrey I., Rodon Ahnert, Jordi, Millward, Michael J., Zhang, Wei, Gao, Ling, Sykes, Amanda, Willard, Melinda D., Yu, Danni, Schade, Andrew E., Crowe, KrisAnne, Flynn, Daniel L., Kaufman, Michael D., Henry, James R., Peng, Sheng-Bin, Benhadji, Karim A., Conti, Ilaria, Gordon, Michael S., Tiu, Ramon V., Hong, David S.
• Format: Journal Article
• Language: English
• Published: United States 01.02.2020
• Subjects: Adult; Aged; Aged, 80 and over; Cell Line, Tumor; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms - drug therapy; Phenylurea Compounds - pharmacology; Phenylurea Compounds - therapeutic use; Pyrimidines - pharmacology; Pyrimidines - therapeutic use; Young Adult

Mutations in ERK signaling drive a significant percentage of malignancies. LY3009120, a pan-RAF and dimer inhibitor, has preclinical activity in RAS- and BRAF-mutated cell lines including BRAF-mutant melanoma resistant to BRAF inhibitors. This multicenter, open-label, phase I clinical trial (NCT0201...